Detection of acquired resistance to anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer using circulating tumor DNA
Not Applicable
Recruiting
- Conditions
- Colorectal cancer
- Registration Number
- JPRN-UMIN000034923
- Lead Sponsor
- Kanazawa University Graduate School of Medicine, Department of Cardiovascular and Internal Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
1. Patients diagnosed as double primary cancer 2. Patients with hereditary cancer syndrome
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms drive acquired resistance to anti-EGFR mAbs in RAS-wildtype metastatic colorectal cancer?
How does circulating tumor DNA analysis compare to traditional biopsy methods for monitoring resistance in mCRC patients?
Which biomarkers in RAS-wildtype CRC are predictive of response to anti-EGFR monoclonal antibody therapies?
What adverse events are associated with anti-EGFR mAb treatment in RAS-wildtype metastatic colorectal cancer patients?
Are there combination therapies that overcome resistance to anti-EGFR mAbs in RAS-mutant colorectal cancer?